Atorvastatin

Generic Name: Atorvastatin

Brand Names: Atorvaliq, Caduet, Lipitor, Lypqozet

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₅FN_₂O_₅

CAS Number: 134523-00-5

Unique Ingredient Identifier: A0JWA85V8F

Background: Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication: Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions: Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures

Associated Therapies: -

Clinical Trials

Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Acetaminophen
Drug: Metformin
Drug: Warfarin
Drug: Atorvastatin
Drug: Digoxin
Drug: HRS9531

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Target Recruit Count: 57

Registration Number: NCT06723691

Locations: 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Enlicitide Decanoate
Drug: Atorvastatin

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT06699355

Locations: 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Not yet recruiting

Conditions: Primary Hypercholesterolemiia
Mixed Dyslipidemia

Interventions: Drug: Bempedoic acid
Drug: Ezetimibe
Drug: Rosuvastatin
Drug: Atorvastatin

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-14

Lead Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Target Recruit Count: 2000

Registration Number: NCT06686615

A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects

Phase 1

Not yet recruiting

Conditions: Healthy Adult Subject
Overweight Subject

Interventions: Drug: Repaglinide
Drug: Atorvastatin
Drug: Digoxin
Drug: Rosuvastatin
Drug: HDM1002

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Target Recruit Count: 30

Registration Number: NCT06601517

Locations: 🇨🇳
Peking University Third Hospital, Beijing, China

A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: Danuglipron
Drug: Atorvastatin
Drug: Rosuvastatin

First Posted Date: 2024-08-22

Last Posted Date: 2024-11-19

Lead Sponsor: Pfizer

Target Recruit Count: 80

Registration Number: NCT06567327

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Qps - Mra, Llc., South Miami, Florida, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States